+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction



Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction



Indian Heart Journal 52(5): 533-539



The benefit of using subcutaneous low molecular weight heparin for the treatment of acute myocardial infarction is not known. The aim of this study was to determine the efficacy of a low molecular weight heparin (dalteparin sodium) for the treatment of acute myocardial infarction in patients not treated with thrombolytic therapy. Twenty-nine cardiological centres from leading hospitals in India participated in this prospective, multicentre, double-blind, placebo-controlled study in two phases which included 1128 patients with acute myocardial infarction. In the acute phase (between day 1 and 3 of admission) all the patients received a weight-adjusted dose of subcutaneous dalteparin (120 IU/kg twice daily). In the second, double-blind phase of acute myocardial infarction, patients were randomised to receive a fixed dose of dalteparin (7,500 IU) or an identical placebo injection for 30 days. A composite primary endpoint of death, reinfarction, recurrence of angina and emergency revascularisation was used. All the 1128 patients with acute myocardial infarction were included in the trial. In the acute phase, the composite primary endpoint was observed in 58 (5.1%) patients. Of 1037 paients who were randomly assigned to receive a fixed dose of dalteparin (n=519) or placebo (n=518), the composite primary event rate was 6.7 percent and 7.0 percent, respectively (RR 0.97; 95% CI 0.62-1.52; p=0.90). To conclude, treatment with dalteparin administered subcutaneously in a weight-adjusted dose of 120 IU/kg twice daily resulted in a lower than expected mortality during the acute phase of myocardial infarction. A lower fixed once daily dose of 7,500 IU during the chronic phase did not confer additional protection.

(PDF emailed within 1 workday: $29.90)

Accession: 046579276

Download citation: RISBibTeXText

PMID: 11256775


Related references

Randomized trial of low molecular weight heparin (Dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study. Journal of the American College of Cardiology 30(4): 962-969, 1997

Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). Journal of the American College of Cardiology 33(3): 627-633, 1999

Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine. Cardiovascular Drugs and Therapy 16(4): 303-309, 2003

The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study. Clinical Cardiology 24(3 Suppl.): I 12-I 14, 2001

Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study. Thrombosis Research 64(5): 579-587, 1991

Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. European Heart Journal 24(10): 897-908, 2003

The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction. Angiology 47(5): 491-499, 1996

Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology: results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA 1 & 2) registries and the myocardial infarction registry (MIR). Acc Current Journal Review 11(2): 16-0, 2002

Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology; results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA 1+2) Registries and the Myocardial Infarction Registry (MIR). European Heart Journal 22(19): 1794-1801, 2001

Effect of heparin coated coiled wire stents on platelet activation during acute intervention in patients with acute myocardial infarction Results of the Berlin Stent Study in Acute Myocardial Infarction. European Heart Journal 21(Abstract Suppl.): 527, August-September, 2000

Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. American Heart Journal 154(6): 1078-84, 1084.E1, 2007

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). American Heart Journal 149(2): 217-226, 2005

Optimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin. Clinical Cardiology 27(1): 3-8, 2004

Low molecular weight heparin in acute myocardial infarction. Journal of the American College of Cardiology 27(2 SUPPL A): 166A, 1996

Acute ischemic heart disease - Global outcomes of ST-elevation myocardial infarction: Comparisons of the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25) registry and trial. American Heart Journal 154(1): 54-60, 2007